Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Sources
sec edgar · verbatim disclosureEach tie, with the sentence that disclosed it. Open a row for the wording and the filing it came from.
“Regeneron is the sole manufacturer of ARCALYST drug substance and will remain so until we complete the technology transfer of the manufacturing process for ARCALYST drug substance to Samsung.”
FILING10-K0001104659-26-019168cik 0001730430
“We have also contracted with Samsung to document the technology transfer and enable commercial manufacturing, if successful.”
FILING10-K0001104659-26-019168cik 0001730430
“In August 2022, we entered into the Genentech License Agreement, pursuant to which we granted Genentech exclusive worldwide rights to develop and commercialize the Genentech Licensed Products.”
FILING10-K0001104659-26-019168cik 0001730430
“Until such time as Huadong is able to manufacture ARCALYST, either on its own or through a third party CDMO, we are its only source of drug supply.”
FILING10-K0001104659-26-019168cik 0001730430
“In connection with our acquisition of Primatope, we acquired the rights to an exclusive license to certain intellectual property rights controlled by BIDMC to make, use, develop and commercialize abiprubart under the BIDMC license agreement (the "BIDMC Agreement").”
FILING10-K0001104659-26-019168cik 0001730430
“In August 2022, we entered into a license agreement (the "Genentech License Agreement") with Genentech, Inc. and F. Hoffmann-La Roche Ltd. (collectively, "Genentech"), pursuant to which we granted Genentech exclusive worldwide rights to develop, manufacture and commercialize vixarelimab and related antibodies (each, a "Genentech Licensed Product").”
FILING10-K0001104659-26-019168cik 0001730430
“In September 2016, the Company entered into an asset purchase agreement (the "Biogen Agreement") with Biogen MA Inc. ("Biogen") to acquire all of Biogen's right, title and interest in and to certain assets used in or relating to vixarelimab and other antibodies covered by certain patent rights, including patents and other intellectual property rights, clinical data, know-how, and clinical drug supply.”
FILING10-K0001104659-26-019168cik 0001730430
“In December 2017, the Company entered into a license agreement (as amended from time to time, the "MedImmune Agreement") with MedImmune, Limited (subsequently acquired by AstraZeneca PLC) ("MedImmune"), pursuant to which MedImmune granted the Company an exclusive, sublicensable, worldwide license to certain intellectual property rights to make, use, develop and commercialize mavrilimumab.”
FILING10-K0001104659-26-019168cik 0001730430
“In December 2024, we initiated a collaborative study agreement with The Mayo Clinic (together with Johns Hopkins University) to investigate the effects of ARCALYST in the treatment of cardiac sarcoidosis.”
FILING10-K0001104659-26-019168cik 0001730430
“In December 2024, we initiated a collaborative study agreement with The Mayo Clinic (together with Johns Hopkins University) to investigate the effects of ARCALYST in the treatment of cardiac sarcoidosis.”
FILING10-K0001104659-26-019168cik 0001730430
Watchlist prices, news filtered to it, and its next report on your desk.
Kiniksa Pharmaceuticals International, plc has 7 disclosed suppliers and 3 disclosed customers. Each one is named in an SEC filing, either Kiniksa Pharmaceuticals International, plc’s own annual report or the counterparty’s, and carries the sentence that discloses it.
Kiniksa Pharmaceuticals International, plc
Price, suppliers and customers from SEC filings, institutional ownership and the next report.
Nasdaq · Pharmaceutical Preparations
Prev close 74.89 · gapped above the open, then crossed back over prior close. High/low 76.51 at 7:15 am ET, 74.54 at 3:15 pm ET.
KNSA (Kiniksa Pharmaceuticals International, plc) has 7 disclosed suppliers and 3 disclosed customers, strongest disclosure first.
Suppliers:
Customers:
Select a tie for the filing sentence that discloses it; select again to open the company. Lines are disclosed suppliers and customers, coloured by industry; the closer to the centre, the more the filings disclose. A dot is green or red by today’s move. Extended: satellites hang off single companies, not bundled sectors.
Largest move on the map today: REGN +0.24%, in healthcare.